{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(8)"],"submitter":["Yhim HY"],"pubmed_abstract":["There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standard immunochemotherapy and central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX). Thirty-three patients with newly diagnosed primary breast DLBCL received six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and four fixed doses of IT-MTX (12 mg). The median age was 50 years (range, 29-75), and all patients were females. According to the CNS-International Prognostic Index, most patients (<i>n</i> = 28) were categorized as the low-risk group. Among the 33 patients, 32 complete"],"journal":["Cancers"],"pagination":["E2192"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7463683"],"repository":["biostudies-literature"],"pubmed_title":["First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial."],"pmcid":["PMC7463683"],"pubmed_authors":["Suh C","Yhim HY","Park Y","Eom HS","Kwak JY","Kim HJ","Kim WS","Kim KH","Yoon DH","Kim SJ","Yang DH","Kim JS"],"additional_accession":[]},"is_claimable":false,"name":"First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial.","description":"There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standard immunochemotherapy and central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX). Thirty-three patients with newly diagnosed primary breast DLBCL received six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and four fixed doses of IT-MTX (12 mg). The median age was 50 years (range, 29-75), and all patients were females. According to the CNS-International Prognostic Index, most patients (<i>n</i> = 28) were categorized as the low-risk group. Among the 33 patients, 32 complete","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2026-05-05T00:38:53.73Z","creation":"2020-09-06T07:05:18Z"},"accession":"S-EPMC7463683","cross_references":{"pubmed":["32781541"],"doi":["10.3390/cancers12082192"]}}